Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Inhaled Anti-Infectives With Extended Lung Retention: Pulmocide Secures Cash To Fund Trials

Executive Summary

When tackling pulmonary infections, getting therapeutics into the lungs that stay there long enough to be effective is the key challenge. Pulmocide has just persuaded investors it is up to the task, raising $30m to fund two clinical programs.

Advertisement

Related Content

Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel